Human papillomaviruses (HPVs) are common sexually transmitted infections that cause both benign and malignant neoplasms. During the past decade, much progress has been made on the development of prophylactic vaccines with efforts culminating in two proof-of-concept trials showing 100% protection against persistent infection with HPV16 alone or both HPV16 and HPV18. An international phase III trial of an HPV/6/11/16/18 virus-like-particle (VLP) vaccine is currently underway. If high-level efficacy is demonstrated the vaccine could be commercially available within 4 years, at which time, we will know how the vaccine performs up to three and a half years after immunization, but we will not know about long-term efficacy and immunogenicity. The public health benefit of an HPV vaccine will only be realized if protection lasts for more than a couple of years. Furthermore, since first generation prophylactic HPV vaccines will target only 2 to 4 of the 38 different genital HPV types, other prevention strategies will continue to be needed. The purpose of this project is three-fold. First, we plan to collect an additional 3 to 4 years of follow up data on vaccine efficacy among a cohort of women who received HPV16 vaccine, HPV6/11/16/18 vaccine or placebo injections in 1999 or 2000 and were followed with bi-annual examinations through January of 2004. Second, among vaccine recipients, we will evaluate changes over time in both the local and systemic immune response to HPV. And third, we propose to follow a cohort of young women from time of first vaginal intercourse to determine whether consistent and correct condom use with all sex acts and partners decreases a woman's risk of HPV infection. In summary, the long-range goal of this project is to improve the effectiveness of both vaccine-based and behavioral strategies for preventing HPV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI038383-12
Application #
7074069
Study Section
Special Emphasis Panel (ZRG1-HOP-N (90))
Program Officer
David, Hagit S
Project Start
1995-05-15
Project End
2010-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
12
Fiscal Year
2006
Total Cost
$641,429
Indirect Cost
Name
University of Washington
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Mitchell, Caroline M; Fredricks, David N; Winer, Rachel L et al. (2012) Effect of sexual debut on vaginal microbiota in a cohort of young women. Obstet Gynecol 120:1306-13
Rowhani-Rahbar, Ali; Alvarez, Frances B; Bryan, Janine T et al. (2012) Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 53:239-43
Winer, Rachel L; Hughes, James P; Feng, Qinghua et al. (2011) Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20:699-707
Winer, Rachel L; Hughes, James P; Feng, Qinghua et al. (2010) Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev 19:1682-5
Winer, Rachel L; Harris, Tiffany G; Xi, Long Fu et al. (2009) Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol 81:713-21
Winer, Rachel L; Hughes, James P; Feng, Qinghua et al. (2009) Comparison of Incident Cervical and Vulvar/Vaginal Human Papillomavirus Infections in Newly Sexually Active Young Women. J Infect Dis :
Rowhani-Rahbar, Ali; Carter, Joseph J; Hawes, Stephen E et al. (2009) Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 200:1452-5
Rowhani-Rahbar, Ali; Hughes, James P; Koutsky, Laura A (2009) Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis 36:261-3
Rowhani-Rahbar, Ali; Mao, Constance; Hughes, James P et al. (2009) Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27:5612-9
Winer, Rachel L; Feng, Qinghua; Hughes, James P et al. (2008) Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197:279-82

Showing the most recent 10 out of 31 publications